Pediatric biobanks are an indispensable resource for the research needed to bring advances in personalized medicine into pediatric medical care. It is unclear how or when these advances in medical care may reach children, but it is unlikely that research in adults will be adequate. We conducted the screening for a hypothetic problem in various European and American pediatric biobanks based on online surveys through e-mail distribution based on the Biobank Economic Modeling Tool (BEMT) questionnaire model. Participants in the survey had work experience in biobanking for at least 3 years or more. Contact information about the survey participants was confirmed on the social networks profiles (LinkedIn), as well as on generally available websites. First, we tried creating a model which can show the pediatric preclinical and basic clinical phase relationship and demonstrate how pediatric biobanking is linked to this process. Furthermore, we tried to look for new trends, and the final goal is to put the acquired knowledge into practice, so medical experts and patients could gain usable benefit from it. We concluded that leading positions must take into account ethical and legal aspects when considering the decision to include children in the biobank collection. However, communication with parents and children is essential. The biobank characteristics influence the biobank's motives to include children in the consent procedure. Moreover, the motives to include children influence how the children are involved in the consent procedure and the extent to which children are able to make voluntary decisions as part of the consent procedure.

Breast cancers are very heterogeneous tissues constituted by epithelial cancer cells and an abnormal tumor microenvironment – cancer-associated fibroblasts (CAFs), activated adipocytes, mesenchymal stem cells (MSCs), and others. The aim of the study is to cancer cells and their microenvironment, which behave like a complex and heterogeneous metabolic ecosystem, where cancer cells can reprogram their metabolism as a result of interaction with the components of the microenvironment. The study was based on cancer stem cells (CSC) that were isolated from breast tumors by magnetic separation (AutoMACS). We used spectrophotometric methods for the measurement of aldehyde dehydrogenase (ALDH) enzymatic activity. For these experiments, we used breast cancer and normal stem cell lines. Analyses showed that the proportion of BRCA+ CSC cells was in accordance with the relatively low percentages of CSCs in BRCA+ tumors. ALHD was significantly higher in the CSCs-high BRCA+ breast cancer and CSCs-low BRCA- breast cancer cells, compared with the CSCs-low BRCA+ breast cancer. Breast cancer from BRCA mutation carriers harbor more “high-energy” cell sub-populations than “low-energy” and have their more aggressive phenotype. Key oncogenic pathways known to be dysregulated in breast cancer also regulate stem-cell behavior.

An in-depth study of the biology of tumor growth will help to identify factors that allow us to understand the pathogenetic mechanisms of the development of ovarian cancer metastasis and progression, as well as to become a theoretical basis for developing new approaches to the treatment of this disease. The aim of this study was to determine immunohistochemical and endothelial criteria for ovarian cancer. The postoperative samples of ovarian tumor tissues were divided into 3 groups: comparison group - ovarian cancer; main group - borderline ovarian tumor; benign ovarian tumors. The study was conducted according to the FIGO 2009 classification. The International Histological Classification of WHO 2013 Female Genital Tumors was used for morphological characteristics. Level of growth factors - sVEGF-A was performed by ELISA using standard test systems (BenderMedSystem, Austria). IGC material studies were performed on serial paraffin sections using a standard method with murine monoclonal antibodies to p53 (clone D0-7. Dilution 1: 100. "Dako"). Ventana Medical Systems, Inc. was used as the detection system. Positive and negative control reactions were performed. The label index (MI) was used to evaluate p53 nuclear expression. WCIF ImageJ and Aperio Image Scope were used to estimate the number and degree of cell staining. Statistical analysis of the obtained data was performed using Statistica 6.0. The results of morphological studies of ovarian cancer showed that in our study patients with serous cancer predominated - 78.5%. The second most frequently diagnosed cancer was undifferentiated. In the second stage of our study, we conducted a comparative analysis of the concentration of p53 in the serum and tissue of patients in the study groups, which showed the existence of significant differences. In patients of the POY and DOY groups, both total and local p53 protein activity were significantly higher than in the comparison group, p <0.05. There was a positive correlation between p53 protein activity in serum and ovarian tissue. Serum VEGF A scores were statistically significantly correlated with the disease stage: Spearman rank correlation coefficient rho = 0.30; 95% CI = 0.02 - 0.536, p <0.05. There were no correlations with patients' age, histological subtype, and degree of tumor differentiation. Considering the results of our study, we can conclude that the criterion-important indicators of QA are serum levels of p53 and the index of serum VEGF A, which is confirmed by the results of ROC analysis p = 0.0026, and indicates a good informativeness of the method.